TLR7 and TLR8 as targets in cancer therapy (Q37051014)

17 August 2017

1 reference

title

TLR7 and TLR8 as targets in cancer therapy (English)

1 reference

17 August 2017

0 references

M P Schön

1

1 reference

PubMed ID

18176600

17 August 2017

M Schön

series ordinal

2

1 reference

PubMed ID

18176600

17 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

17 August 2017

1 reference

17 August 2017

27

1 reference

17 August 2017

2

1 reference

17 August 2017

190-199

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210913

17 August 2017

0 references

cites work

Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod-induced interleukin-1 alpha stimulation improves barrier homeostasis in aged murine epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Interventions for basal cell carcinoma of the skin: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

The immune response modifier resiquimod mimics CD40-induced B cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Efficacy of S26308 against guinea pig cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod 5% cream in the treatment of mycosis fungoides--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod and resiquimod as novel immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod in basal cell carcinoma: how does it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

A pilot study of treatment of lentigo maligna with 5% imiquimod cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod for actinic keratosis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

The Toll‐like receptor 7 (TLR7)‐specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Topical immunomodulation in dermatology: potential of toll-like receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod: a topically applied link between innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod in the treatment of extensive recurrent lentigo maligna

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Toll-Like Receptor Ligands Modulate Dendritic Cells to Augment Cytomegalovirus- and HIV-1-Specific T Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Recognition of single-stranded RNA viruses by Toll-like receptor 7

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

New insights into the regulation of TLR signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Immunomodulation as a treatment strategy for genital herpes: review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Treatment of Bowen's disease with imiquimod 5% cream in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

TLR8-mediated NF-κB and JNK Activation Are TAK1-independent and MEKK3-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

The evolution of vertebrate Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

The antitumoral mode of action of imiquimod and other imidazoquinolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Role of Toll-like receptors in costimulating cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Topically applied imiquimod inhibits vascular tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Opposing actions of STAT-1 and STAT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Topical imiquimod in the treatment of metastatic melanoma to skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Treatment of cutaneous metastatic melanoma with imiquimod 5% cream and the pulsed-dye laser

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Cellular Requirements for Cytokine Production in Response to the Immunomodulators Imiquimod and S-27609

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Successful treatment of vulval melanoma in situ with topical 5% imiquimod cream

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

The immunostimulatory compound 7-allyl-8-oxoguanosine (loxoribine) induces a distinct subset of murine cytokines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Cytokine induction in mice by the immunomodulator imiquimod.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Imiquimod, a topical immune response modifier, induces migration of Langerhans cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210913

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210913

1 reference

17 August 2017

1 reference

PubMed ID

18176600